The Foundation Institute San Raffaele G. Giglio of Cefalù   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Pisciotto Italy (2003)

Organization Overview

First Clinical Trial
2012
NCT01473277
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

IRCCS Ospedale san Raffaele | IRCCS San Raffaele Scientific Institute | IRCCS San Raffaele Scientific Institute, Milan, Italy | Istituto S. Raffaele, Milan | Istituto S. Raffaele, Milan, Italy Giuseppe Saglio, Institute of Hematology, Ospedale Mauriziano, Turin, Italy | Ospedale (Hospital) San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET) | Ospedale San Rafafele | Ospedale San Raffaele IRCCS S.r.l. | Ospedale San Raffaele - Telethon Institute for Gene Therapy (OSR-TIGET) | Piemonti Lorenzo | San raffaele hospital | San Raffaele Telethon Institute of Gene Therapy | San Raffaele Telethon Institute of Gene Therapy (SR-TIGET) | Scientif Institute San Raffale

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 2)

Cardiomyopathy, Hypertrophic (Phase 2)

Cataract (Phase 3)

Critical Illness (Phase 4)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Febrile Neutropenia (Phase 2)

Hypertension (Phase 3)

Hypertrophy (Phase 2)

Inflammation (Phase 3)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukodystrophy, Metachromatic (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lysosomal Storage Diseases (Phase 3)

Necrosis (Phase 2)

Paresis (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Shoulder Pain (Phase 2)

Syndrome (Phase 2)

Wiskott-Aldrich Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 27